drugset / Trial / NCT04958473
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
In patients with recurrent or metastatic renal cell carcinoma, a preliminary evaluation of the safety and efficacy of sintilimab combined with axitinib in patients with advanced renal cell carcinoma was conducted.Progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and disease remission rate (ORR) were evaluated.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2022-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |